載入...
Bispecific antibodies in cancer immunotherapy
Following the clinical success of immune checkpoint antibodies targeting CTLA-4, PD-1 or PD-L1 in cancer treatment, bispecific antibodies are now emerging as a growing class of immunotherapies with potential to further improve clinical efficacy and safety. We describe three classes of immunotherapeu...
Na minha lista:
| 發表在: | Ther Adv Vaccines Immunother |
|---|---|
| Main Authors: | , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
SAGE Publications
2018
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5933537/ https://ncbi.nlm.nih.gov/pubmed/29998217 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2515135518763280 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|